Back to Search Start Over

Randomised clinical trial: individualised vs. weight-based dosing of azathioprine in Crohn's disease

Authors :
Hanauer, S. B.
Dassopoulos, T.
Martin, C. F.
Dubinsky, M. C.
Sandler, R. S.
Seidman, E. G.
Galanko, J. A.
Bentsen, J. L.
Publication Year :
2014
Publisher :
The University of North Carolina at Chapel Hill University Libraries, 2014.

Abstract

Azathioprine (AZA), a pro-drug metabolized to the active metabolites 6-thioguanine nucleotides (6TGN), is a steroid-sparing therapy for Crohn’s disease (CD). This trial investigated whether AZA therapy is optimized by individualized dosing based on thiopurine methyltransferase (TPMT) activity and 6TGN concentrations.

Details

Language :
English
Database :
OpenAIRE
Accession number :
edsair.doi...........a3721623ba5e9b9be131647e1aba8e48
Full Text :
https://doi.org/10.17615/7jxn-w918